Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
asidna
- Development stage
- Phase 2
- Lead developer
- Valerio Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
AsiDNA is a first-in-class signal-interfering DNA (siDNA) molecule designed to disrupt the DNA damage response (DDR) in cancer cells. It consists of a short, cholesterol-conjugated, double-stranded DNA oligonucleotide that mimics genomic double-strand breaks. By acting as a decoy, AsiDNA binds to and hyperactivates key DNA repair proteins, including DNA-dependent protein kinase (DNA-PK) and poly(ADP-ribose) polymerase (PARP), effectively sequestering them away from actual sites of DNA damage caused by radiotherapy or chemotherapy. This mechanism prevents the repair of lethal DNA lesions, leading to selective tumor cell death while sparing healthy cells. Developed by Onxeo, AsiDNA is being evaluated in clinical trials for various solid tumors, including breast cancer and ovarian cancer, particularly in combination with DNA-damaging agents or PARP inhibitors to overcome resistance.
- Brand names
- AsiDNA
- Other names
- DbaitCo-DbaitsiDNA
02
Targets
DNA-PK (DNA-dependent protein kinase)ATM (Ataxia telangiectasia mutated protein)
Beyond the preview
Go deeper on asidna.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on asidna.